Screener
Cullinan Therapeutics, Inc. CGEM Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336717
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Investing activities: | ||
| Maturities of marketable securities | 107,799 | 294,572 |
| Purchases of marketable securities | (34,707) | (204,366) |
| Net cash provided by investing activities | 73,092 | 90,206 |
| Financing activities: | ||
| Issuance of common stock under equity-based compensation plans | 1,480 | 373 |
| Net cash provided by financing activities | 1,480 | 373 |
| Net decrease in cash and cash equivalents | (9,692) | (10,185) |
Item 1. Financial Statements.
FAQ
- What is Cullinan Therapeutics, Inc.'s investing cash flow?
- Cullinan Therapeutics, Inc. (CGEM) reported investing cash flow of $40.68M in Q2 2026.
- How has Cullinan Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Cullinan Therapeutics, Inc.'s investing cash flow decreased by 23.8% year-over-year, from $53.4M to $40.68M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s investing cash flow?
- Over 2 years (2021 to 2025), Cullinan Therapeutics, Inc.'s investing cash flow has grown at a -26.6% compound annual growth rate (CAGR), from -$333.78M to $179.99M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Cullinan Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude